FDA Approves TEVA's Cassipa to Treat Opioid Dependence
2018年9月8日 - 7:09AM
Dow Jones News
By Stephen Nakrosis
Teva Pharmaceuticals USA Inc. on Friday received approval from
the U.S. Food and Drug Administration for its drug Cassipa to be
used in the treatment of opioid dependence.
The FDA said the new action also provides a new dosage strength
of buprenorphine and naloxone sublingual film, which are applied
under the tongue, in both brand name and generic versions and in
various strengths.
FDA Commissioner Scott Gottlieb said "The FDA is committed to
helping those with opioid use disorder transition to lives of
sobriety. We've taken a number of steps to advance the development
of new FDA-approved treatments for opioid dependence and encourage
health care professionals to ensure patients are offered an
adequate chance to benefit from these therapies."
Teva Pharmaceuticals USA Inc. is a division of Teva
Pharmaceuticals Industries Ltd. (TEVA).
American Depository Receipts of Teva finished Friday trading
down 1.15%, to $21.50, after Credit Suisse downgraded the stock to
neutral on concerns the FDA's upcoming decision on Teva's migraine
drug may not go well, and will weigh on the shares. In after-hours
trading Friday, Teva's ADRs were down 0.09% to $21.48.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
September 07, 2018 17:54 ET (21:54 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Teva Pharmaceutical Indu... (NYSE:TEVA)
過去 株価チャート
から 6 2024 まで 7 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
過去 株価チャート
から 7 2023 まで 7 2024
